ArcherDX Revenue and Competitors

Claim your profile

Boulder, CO USA

Location

$150M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ArcherDX's estimated annual revenue is currently $4.8M per year.(i)
  • ArcherDX received $35.0M in venture funding in March 2018.
  • ArcherDX's estimated revenue per employee is $77,500
  • ArcherDX's total funding is $150M.

Employee Data

  • ArcherDX has 62 Employees.(i)
  • ArcherDX grew their employee count by -35% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$63.7M41112%N/AN/A
#2
$7.8M5032%N/AN/A
#3
$1.9M31-24%N/AN/A
#4
$1.9M12-25%N/AN/A
#5
$15.8M102-11%$29MN/A
#6
$4.8M3194%N/AN/A
#7
$3.3M215%N/AN/A
#8
$1.6M20-29%$13.9MN/A
#9
$3.5M35-19%$90.4MN/A
#10
$0.5M70%$1MN/A

ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$150M

Total Funding

62

Number of Employees

$4.8M

Revenue (est)

-35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ArcherDX News

2022-04-19 - Gene-editing company seeks incentives for large-scale Louisville expansion

... Genapsys Inc. has operations in Westminster; Invitae Corp., a medical-genetics company, acquired Boulder-based ArcherDX in late 2020;...

2022-03-30 - Foresight Diagnostics Announces the Hiring of Sandra Close, Ph.D ...

Close has served as an executive leader in both diagnostic and pharmaceutical companies, including at ArcherDX/Invitae and Eli Lilly, among...

2022-03-22 - Immune Repertoire Sequencing Market Technological ...

... Growth Opportunity and Forecast 2022-2028 | Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG,.

2019-12-17 - Boulder Biotech Company Lands $55M for Personalized Genomic Medicine

Boulder's ArcherDX, a biotech company developing personalized genomic medicine, announced it closed a $55 million Series C round to grow its commercial footprint and further its product offerings. The round was led by Perceptive Advisors, which was joined by new investors Redmile Group, Soleus ...

2019-12-17 - ArcherDX Closes $55M Series C Financing

ArcherDX, Inc., a Boulder, Colo.-based molecular diagnostics company dedicated to developing solutions that advance the application of personalized genomic medicine, closed a $55m Series C financing. The round was led by Perceptive Advisors, which was joined by new investors Redmile Group, Sole ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M620%N/A
#2
$7.8M625%N/A
#3
$10M6263%N/A
#4
$7.5M6268%N/A
#5
$7.5M6222%N/A

ArcherDX Funding

DateAmountRoundLead InvestorsReference
2018-03-21$35.0MABoulder Ventures, Ltd.Article